Literature DB >> 25448104

Development of a subunit vaccine containing recombinant Riemerella anatipestifer outer membrane protein A and CpG ODN adjuvant.

Chun-Yen Chu1, Chia-Hui Liu1, Jhong-Jie Liou1, Jai-Wei Lee2, Li-Ting Cheng3.   

Abstract

Riemerella anatipestifer, a Gram-negative bacillus, causes septicemia that can result in high mortality for ducklings. In this study, we evaluated the immune response and protective efficacy provided by a subunit vaccine containing recombinant outer membrane protein A (rOmpA) and plasmid constructs containing CpG oligodeoxynucleotides (ODN). Results showed that CpG ODN enhanced both humoral and cell-mediated immunity elicited by rOmpA as early as two weeks after primary immunization. When compared to ducks immunized with rOmpA, ducks immunized with rOmpA+CpG ODN showed higher levels (p<0.05) of antibody titer, T cell proliferation, and percentages of CD4(+) and CD8(+) T cell in peripheral blood mononuclear cells (PBMCs). The relative fold inductions of mRNA expression of Th1-type (IFN-γ and IL-12), and Th2-type (IL-6) cytokines in PBMCs isolated from ducks immunized with rOmpA+CpG ODN were significantly higher than those of the rOmpA group. Homologous challenge result showed that the rOmpA+CpG ODN vaccine reduced the pathological score by 90% in comparison with the saline control. In conclusion, our study found that CpG ODN can enhance both humoral and cellular immunity elicited by a rOmpA vaccine. The rOmpA+CpG ODN vaccine can be further developed as a subunit vaccine against R. anatipestifer.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CpG adjuvant; Duck; OmpA; Riemerella anatipestifer; Subunit vaccine

Mesh:

Substances:

Year:  2014        PMID: 25448104     DOI: 10.1016/j.vaccine.2014.11.010

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  Epidemiology and Antibiogram of Riemerella Anatipestifer Isolated from Waterfowl Slaughterhouses in Taiwan.

Authors:  Fei-Fei Chang; Chang-Chieh Chen; Shao-Hung Wang; Chiou-Lin Chen
Journal:  J Vet Res       Date:  2019-03-22       Impact factor: 1.744

2.  Riemerella anatipestifer infection in ducks induces IL-17A production, but not IL-23p19.

Authors:  Rochelle A Flores; Cherry P Fernandez-Colorado; Fahmida Afrin; Paula Leona T Cammayo; Suk Kim; Woo H Kim; Wongi Min
Journal:  Sci Rep       Date:  2019-09-13       Impact factor: 4.379

3.  Evaluation of Long-term Antibody Response and Cross-serotype Reaction in Ducks Immunised with Recombinant Riemerella Anatipestifer Outer Membrane Protein A and CpG ODN.

Authors:  May Phonvisay; Jai-Wei Lee; Jhong-Jie Liou; Hsian-Yu Wang; Chun-Yen Chu
Journal:  J Vet Res       Date:  2019-11-16       Impact factor: 1.744

4.  In vitro susceptibility of four antimicrobials against Riemerella anatipestifer isolates: a comparison of minimum inhibitory concentrations and mutant prevention concentrations for ceftiofur, cefquinome, florfenicol, and tilmicosin.

Authors:  Yafei Li; Yanan Zhang; Huanzhong Ding; Xian Mei; Wei Liu; Jiaxiong Zeng; Zhenling Zeng
Journal:  BMC Vet Res       Date:  2016-11-09       Impact factor: 2.741

5.  Development of a colloidal gold immunochromatographic strip for rapid detection of Riemerella anatipestifer in ducks.

Authors:  Wenlong Han; Zongchao Chen; Pengfei Niu; Xiaomei Ren; Chan Ding; Shengqing Yu
Journal:  Poult Sci       Date:  2020-07-03       Impact factor: 3.352

6.  Toll-Like Receptor 21 of Chicken and Duck Recognize a Broad Array of Immunostimulatory CpG-oligodeoxynucleotide Sequences.

Authors:  Yu-Chen Chuang; Jen-Chih Tseng; Jing-Xing Yang; Yi-Ling Liu; Da-Wei Yeh; Chao-Yang Lai; Guann-Yi Yu; Li-Chung Hsu; Chun-Ming Huang; Tsung-Hsien Chuang
Journal:  Vaccines (Basel)       Date:  2020-11-02

7.  Therapeutic Injection of a C-Type CpG ODN Induced an Antitumor Immune Response in C57/BL6 Mice of Orthotopically Transplanted Hepatocellular Carcinoma.

Authors:  Huijie Jia; Tiesuo Zhao; Di Zou; Xiaolong Jia; Ji Gao; Xiangfeng Song
Journal:  Oncol Res       Date:  2016       Impact factor: 5.574

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.